Bg Medicine (BGMD)
OTHER OTC:BGMD
BGMD Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.02
Previous CloseN/A
Volume5.91K
Average Volume (3M)N/A
Market Cap
$11.00
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-51.80
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding11,374,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BGMD FAQ
What was Bg Medicine’s price range in the past 12 months?
Bg Medicine lowest stock price was $0.02 and its highest was $0.02 in the past 12 months.
What is Bg Medicine’s market cap?
Bg Medicine’s market cap is $11.00.
When is Bg Medicine’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bg Medicine’s earnings last quarter?
Currently, no data Available
Is Bg Medicine overvalued?
According to Wall Street analysts Bg Medicine’s price is currently Overvalued.
Does Bg Medicine pay dividends?
Bg Medicine does not currently pay dividends.
What is Bg Medicine’s EPS estimate?
Bg Medicine’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bg Medicine have?
Bg Medicine has 11,374,000 shares outstanding.
What happened to Bg Medicine’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bg Medicine?
Currently, no hedge funds are holding shares in BGMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bg Medicine
BG Medicine, Inc. is dedicated to the development and commercialization of diagnostic products aimed at guiding patient care for individuals in the United States afflicted with heart failure and related conditions. Its product portfolio includes the BGM Galectin-3 Test, an in vitro diagnostic solution that quantifies galectin-3 levels in blood serum or plasma using an enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform. Additionally, the company provides the CardioSCORE Test, a multi-analyte, biomarker-based blood test designed to assess the short-term risk of atherothrombotic cardiovascular events, such as myocardial infarction (heart attack) and ischemic stroke. BG Medicine maintains licensing, development, and commercialization agreements with major partners like Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc., specifically for automated versions of its galectin-3 test. Furthermore, it has forged a strategic alliance with Abbott Laboratories to jointly develop and market galectin-3 assay kits, along with their corresponding control kits and calibrators. Founded in 2000, the company was initially known as Beyond Genomics, Inc., before rebranding to BG Medicine, Inc. in October 2004. Its corporate headquarters are located in Waltham, Massachusetts.